Sponsors

Molecular testing for human papillomavirus

Cepheid has released performance data for its Xpert HPV, currently in clinical trials with a targeted CE-IVD release this year. “We’re pleased with the early Xpert HPV data that highlight Cepheid’s commitment to delivering tests that offer the unmatched combination of performance, ease of use and speed that our customers expect,” said John Bishop, Cepheid’s chairman and CEO. (Image: National Cancer Institute/Laboratory of Tumor Virus Biology)

“Highlighting Cepheid’s history of innovation, the GeneXpert system delivers the ‘sample-in, answer-out’ molecular testing solution that defines the essential capability for broad market dissemination that many others are aspiring to bring to market,” continued Mr Bishop. “Our GeneXpert System now has an installed base of more than 5000 systems in 139 countries, with a menu of 14 available Xpert tests spanning healthcare-associated infections, critical infectious disease and sexual health.”  Xpert HPV is a multiplexed test that targets the E6/E7 region of 14 cancer-related HPV types, specifically types 16 and 18/45 in separate detection channels, with 11 other high-risk types detected in combined channels.
www.cepheid.com

Latest Issues

Introduction to Cellular Components, Tissue Morphology and Tissue Recognition Master Class

The Haylofts, St Thomas Street, Haymarket, Newcastle, NE1 4LE, UK
7 April, 2026

Microbiology Society Annual Conference 2026

ICC Belfast, Northern Ireland
13 - 16 April, 2026

39th International Symposium on Technical Innovations in Laboratory Hematology

Edinburgh International Convention Centre
17-19 April, 2026

ESCMID Global 2026

Messe München Munich, Germany
17-21 April, 2026